U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223528) titled 'TEPH: Telaglenastat Efficacy in Pulmonary Hypertension' on Oct. 21.
Brief Summary: The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH). PH is a progressive condition that affects the arteries in the lungs, specifically the pulmonary arteries, which carry blood from the right side of the heart to the lungs. Telaglenastat is not currently approved by the Food and Drug Administration for the treatment of PH. However, the study investigators believe that Telaglenastat may help lower blood pressure in the lungs and improve both heart and lu...